Ribavirin in chronic hepatitis C: Past and future

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 3, 2009, Pages 249-253

  Loustaud Ratti, Véronique ^a   Rousseau, Annick ^b   Marquet, Pierre ^b   Denis, François ^c   Alain, Sophie ^c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b Univ Limoges   (France)

^c UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ERYTHROPOIETIN; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ANEMIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; EDITORIAL; ENZYME INHIBITION; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MAINTENANCE DRUG DOSE; RNA SYNTHESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VIRUS REPLICATION; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATITIS C VIRUS; METHODOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 85047684976     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.5     Document Type: Editorial

References (46)

1. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
3. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
4. Heathcote J, Zeuzem S. Pegylated interferon monotherapy for chronic hepatitis C. Semin. Liver Dis. 24(Suppl. 2), 39-45 (2004).
5. Bronowicki JP, Ouzan D, Asselah T et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon α-2a plus ribavirin Gastroenterology 131, 1040-1048 (2006).
6. Dusheiko GM, Hezode C, Pol S. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon α 2A with or without ribavirin: further interim analysis. Results of the Prove 2 study. J. Hepatol. 48(Suppl. 2), S26 (2008).
7. Jen J, Laughlin M, Chung C et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin. Pharmacol. Ther. 72, 349-361 (2002).
8. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob. Agents Chemother. 47, 124-129 (2003).
9. Loustaud-Ratti V, Alain S, Rousseau A et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 47, 1453-1461 (2008).
10. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir. Ther. 13(4), 607-611 (2008).
11. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur. J. Epidemiol. 2, 1-14 (1986).
12. Murata Y, Falsey AR. Respiratory syncytial virus infection in adults. Antivir. Ther. 12, 659-670 (2007).
13. Snell NJ. Ribavirin current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother. 2, 1317-1324 (2001).
14. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 337, 1058-1061 (1991).
15. Brillanti S, Garson J, Foli M et al. A pilot study of combination therapy with ribavirin plus interferon α for interferon α-resistant chronic hepatitis C. Gastroenterology 107, 812-817 (1994).
16. Di Bisceglie AM, Conjeevaram HS, Fried MW et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123, 897-903 (1995).
17. McHutchison JG, Manns M, Patel K et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123, 1061-1069 (2002).
18. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41 (2), 275-279 (2005).
19. Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol. Life Sci. 63, 832-842 (2006).
20. Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with α interferon. Antimicrob. Agents Chemother. 44(4), 859-866 (2000).
21. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310, 333-342 (2003).
22. Asahina Y, Izumi N, Enomoto N et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 43, 623-629 (2005).
23. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81, 7732-7741 (2007).
24. Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46, 1548-1563 (2007).
25. Neumann AU, Lam NP, Dahari H et al. Hepatitis C vial dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103-107 (1998).
26. Pawlotsky JM, Dahari H, Neumann AU et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126, 703-714 (2004).
27. Bruchfeld A, Lindahl K, Schvarcz R, Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther. Drug Monit. 24, 701-708 (2002).
28. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther. Drug Monit. 22, 555-565 (2000).
29. Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br. J. Clin. Pharmacol. 49, 417-421 (2000).
30. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br. J. Clin. Pharmacol. 62, 710-714 (2006).
31. Glue P. The clinical pharmacology of ribavirin. Semin. Liver Dis. 19, 17-24 (1999).
32. De Franceschi L, Fattovich G, Turrini F. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31(4), 997-1004 (2000).
33. Gaeta GB, Precone DF, Felaco FM et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 16, 1633-1639 (2002).
34. Dieterich DT, Wasserman R, Bräu N et al. Once-weekly epoetin α improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon α. Am. J. Gastroenterol. 98, 2491-2499 (2003).
35. Afdhal NH, Dieterich DT, Pockros PJ et al.; Proactive Study Group. Epoetin α maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126, 1302-1311 (2004).
36. Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin α. Hepatology 46, 371-379 (2007).
37. Crespo M, Pou L, Esteban JI et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir. Ther. 12, 1217-1223 (2007).
38. Marcellin P, Jensen DM, Hadzyiannis SJ, Ferenci P. Differnciation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR(pEVR), allows a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon α 2a and ribavirin. Hepatology 46, 818A (2007).
39. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon α-2a (40 KD)/ribavirin. J. Hepatol. 43, 425-433 (2005).
40. Nicot F, Legrand-Abravanel F, Lafont T et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J. Med. Virol. 80, 1523-1529 (2008).
41. Christensen PB, Alsio AA, Buhl MR et al. Ribavirin concentration at W4 is an independent predictor for sustained virological response after treatment of hepatitis C genotype 2/3 (Nordynamic trial). J. Hepatol. 48(Suppl. 2), S6-S7 (2008).
42. Arase Y, Ikeda K, Tsubota A et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 48, 138-144 (2005).
43. Donnerer J, Grahovac M, Stelzl E et al. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology 76, 136-140 (2006).
44. Rendón AL, Núñez M, Romero M et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J. Acquir. Immune Defic. Syndr. 39, 401-405 (2005).
45. Bosch ME, Sánchez AJ, Rojas FS, Ojeda CB. Ribavirin: analytical determinations since the origin until today. J. Pharm. Biomed. Anal. 45, 185-193 (2007).
46. Dahari H, Markatou M, Zeremski M et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/ HCV co-infected patients during treatment with pegylated interferon and ribavirin. J. Hepatol. 47, 23-30 (2007).